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Congenital heart disease (CHD) is one of the most commonly occurring con-genital anomalies in the general population. In patients with Diamond Black-fan anemia (DBA)—a rare inherited bone marrow failure syndrome—CHD 
represents ≈30% of all congenital anomalies.1 Affected individuals within multi-
plex families may have hematologic manifestations with or without CHD or have 
CHD alone. To support a link between these 2 conditions, we hypothesized that 
because CHD is common in the Diamond Blackfan Anemia Registry (DBAR) cohort, 
there are patients with occult DBA in the general CHD population. This study could 
reveal new knowledge regarding the pathogenesis of nonsyndromic CHD.
DBA, characterized by hypoproliferative, proapoptotic erythropoiesis and red 
cell failure, birth defects, growth failure, and cancer predisposition, presents 
with hypoplastic anemia; median age, 2 months. Inactivating mutations in large 
or small subunit-associated RP (ribosomal protein) genes are found in 65% to 
70% of cases. RP-associated DBA has autosomal dominant inheritance with 
variable penetrance or presents as sporadic new dominant mutations. A few 
cases are not RP associated.1,2 The DBAR of North America, established in 1991, 
captures patients in a nonbiased fashion.1 In the DBAR (n=744), 111 patients 
have CHD, representing a significantly greater prevalence of CHD in patients 
with DBA (n=111 of 744; prevalence, 1491.9/10 000; 14.9%) compared with 
the general population3 (n=3240 of 398 140; prevalence, 81.4/10 000; <1%; 
P<0.0001 [χ2]). The relative distribution of CHD in DBA is similar to the general 
population (Figure).
To determine the prevalence of occult DBA presenting as CHD, we evaluated 102 
unselected patients with CHD followed by Pediatric Cardiology (after IRB approved 
informed consent). Inclusion criteria were age >6 months (75% of patients with 
DBA present before 6 months of age), no known syndrome associated with CHD, 
and no history of red cell transfusion in the past 120 days. Erythrocyte adenosine 
deaminase activity (sensitive [84%], highly specific [95%], and stable marker for 
DBA throughout life)4 and complete blood count were determined on each patient. 
Five patients, aged 6 months to 4 years, with a vascular ring, tetralogy of Fallot, 
and transposition of great vessels and 2 with complete atrioventricular canal with 
double outlet right ventricle, respectively, were found to have elevated erythrocyte 
adenosine deaminase activity (range, 1.01–1.35 EU/gm Hb; normal, 0.33–0.96) 
characteristic of DBA.4 None of the patients had macrocytosis—a classical finding; 
1 patient had mild anemia. Genetic analysis revealed 1 patient to be heterozygous 
for a mutation in RPS24, c.91G>A (p.Gly31Arg)—a variant of unknown signifi-
cance. The glycine residue at position 31 adjacent to invariant positions of RPS24 is 
relatively conserved across species. This variant was described likely pathogenic by 
prediction tools. Ribosomal RNA processing by Northern blot analysis was charac-
teristic of the RPS24 mutation (Figure).
RESEARCH LETTER
Increased Prevalence of Congenital Heart Disease in 
Children With Diamond Blackfan Anemia Suggests 
Unrecognized Diamond Blackfan Anemia as a Cause 
of Congenital Heart Disease in the General Population
A Report of the Diamond Blackfan Anemia Registry
© 2018 American Heart Association, Inc.
http://circgenetics.ahajournals.org.
Circulation: Genomic and Precision Medicine
*Drs Vlachos and Osorio are joint first 
authors.
†Drs Ellis and Lipton contributed equally 
to this work.
Key Words: anemia, Diamond 
Blackfan ◼ child ◼ human genetics 
◼ humans ◼ mutation
February132018
D
ow
nloaded from
 http://ahajournals.org by on September 14, 2018
Vlachos et al; CHD in DBA Suggests Unrecognized DBA in CHD Patients
2Circ Genom Precis Med. 2018;11:e002044. DOI: 10.1161/CIRCGENETICS.117.002044 May 2018
The patient was born at term with complex CHD; 
double outlet right ventricle, complete atrioventric-
ular canal, and pulmonary stenosis with heterotaxy 
syndrome (asplenia, levocardia, juxtaposition of the 
aorta and inferior vena cava, right-sided stomach, 
and intestinal malrotation). Complete blood count at 
Figure. Congenital heart disease (CHD) in Diamond Blackfan anemia (DBA).  
A, The CHD anomalies in the Diamond Blackfan Anemia Registry (DBAR) included ventricular septal defect (VSD; 44%), 
atrial septal defect (ASD; 32.5%), coarctation of the aorta (CoA; 4.4%), pulmonic valve stenosis (PS; 5.3%), tetralogy 
of Fallot (TOF; 3.5%), aortic valve stenosis (AS; 2.6%), total anomalous pulmonary venous return (TAPVR; 0.9%), and 
others (7%). Patent ductus arteriosus and patent foramen ovale were not included. The defects were similar in relative 
frequency to those found in the general CHD population,3 with VSD, ASD, CoA, PS, and TOF being the 5 most com-
mon CHD diagnoses in the DBAR but with the exception that there were no cases of tricuspid atresia (TVA), pulmo-
nary atresia (PVA), hypoplastic left heart syndrome (HLHS), dextro-transposition of the great arteries (D-TGA), truncus 
arteriosus (TA), or atrioventricular canal (AVC). Because of the limited size, it is difficult to ascertain whether any of the 
diagnoses not found are truly underrepresented in the DBAR. However, restricting the analysis to age ≥6 mo likely pre-
cludes representative enrollment of patients with severe fatal lesions. The absence of AVC defects in the DBAR cohort 
can be explained by the fact that most AVC defects in the general population are usually seen in relation to syndromes, 
in particular, Down syndrome. B, Northern blot analysis of pre-rRNA processing was performed on total RNA isolated 
from primary peripheral blood mononuclear cells (left) on the DBAR patient and immortalized lymphoblastoid cells lines 
(right) from the Italian patient and healthy controls, respectively. Protein translations of mutational genotypes for index 
patients are shown above appropriate lanes. The membranes were interrogated with a probe against the 5′ end of 
internal spacer region 1 represented as the asterisk above the schematic views of pre-rRNA species shown to the right. 
The values shown below each lane represent the ratio of phosphorimage units derived for 30S and 18SE species in each 
lane demonstrate increased 30S pre-rRNA and diminished 18SE, consistent with a pre-rRNA processing defect reported 
in patients with RPS24 mutations.
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15 months of age revealed hemoglobin, 17.5 g/dL; 
hematocrit, 51.3%; mean corpuscular volume, 87.3 
fL; and reticulocyte count, 1.8%, at 3.5 years of age, 
he remains hematologically normal. Genetic testing 
revealed the same RPS24 mutation in the father who 
has an essentially normal complete blood count and 
no CHD.
The analysis was extended to patients within the Ital-
ian Italian DBA registry where 1 patient had an atrioven-
tricular canal defect and a mutation in RPS24, c.64C>T 
(p.Gln22Ter). This variant was inherited by this patient’s 
son who also had an atrioventricular canal defect, ele-
vated erythrocyte adenosine deaminase activity, and 
abnormal rRNA processing (Figure) but no overt hema-
tologic abnormalities.
In summary, CHD is significantly more prevalent 
among those with DBA than in the general popula-
tion, and subclinical blood abnormalities characteristic 
of variably penetrant DBA may be detectable among 
those patients with CHD, supporting that they are 
linked. The distribution of CHD in patients with DBA 
seems to be similar to the general population. We iden-
tify 2 individuals from unrelated families with mutations 
in RPS24 for whom CHD is the only clinical manifesta-
tion of DBA. Both have mutations suggestive of loss of 
function with incomplete penetrance in both the hema-
tologic and CHD phenotypes.
Elevated erythrocyte adenosine deaminase activity 
in unselected patients with CHD was noted in 5 of 
102 patients with 1 confirmed to have occult DBA 
caused by a loss-of-function RPS24 mutation. Further 
analysis of other CHD cohorts will be necessary to 
estimate the prevalence of DBA in the general CHD 
population because the variable penetrance of the 
DBA phenotype can be associated with the occur-
rence of congenital anomalies without the classic 
hematologic findings.
Changes in the dosage of genes that transcriptional-
ly regulate cardiogenesis have been proposed to lead to 
CHD.5 The similarity in distribution of CHD in both the 
DBAR and general population suggests that disrupted 
translation caused by RP haploinsufficiency in DBA, 
similarly reducing gene dosage, may be an unrecog-
nized cause of CHD. Studies to detect loss-of-function 
germline mutations in RP genes in patients with CHD 
are likely to reveal additional patients similar to those 
described herein.
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